BSP Pharmaceuticals vs Charles River Laboratories: CDMO Comparison
How does BSP Pharmaceuticals compare to Charles River Laboratories for ADC manufacturing?
Side-by-side comparison of BSP Pharmaceuticals and Charles River Laboratories on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Charles River Laboratories has more FDA inspections on record (9 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Charles River Laboratories maintains 2 MHRA / UK GMP certificates; BSP Pharmaceuticals does not.
On a 13-modality CDMO landscape, both BSP Pharmaceuticals and Charles River Laboratories qualify as ADC manufacturers; Charles River Laboratories carries the higher composite Signal Score for ADC programs in this comparison.
What to evaluate for ADC programs
Both BSP Pharmaceuticals and Charles River Laboratories qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Frequently asked: BSP Pharmaceuticals vs Charles River Laboratories
How does BSP Pharmaceuticals compare to Charles River Laboratories for ADC manufacturing?
On CDMO Signal's composite Signal Score, BSP Pharmaceuticals is 78/100 and Charles River Laboratories is 86/100; BSP Pharmaceuticals has 1 FDA inspection on record vs 9 for Charles River Laboratories; European coverage is 15 active EMA+MHRA certificates for BSP Pharmaceuticals vs 11 for Charles River Laboratories. Both are tracked in the CDMO Signal directory as ADC CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, BSP Pharmaceuticals or Charles River Laboratories?
Both BSP Pharmaceuticals and Charles River Laboratories maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BSP Pharmaceuticals has 1 FDA inspection on record; Charles River Laboratories has 9.
How do BSP Pharmaceuticals and Charles River Laboratories compare on European GMP coverage?
BSP Pharmaceuticals holds 15 active EMA GMP certificates and 0 MHRA / UK certificates. Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for ADC manufacturing — BSP Pharmaceuticals or Charles River Laboratories?
Both BSP Pharmaceuticals and Charles River Laboratories are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BSP Pharmaceuticals carries a Signal Score of 78/100 and Charles River Laboratories carries 86/100 — a small lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →